Valeant eyes tuck-in buys from Salix, Dendreon deals
Feb 23 (Reuters) - Valeant Pharmaceuticals International Inc will use its new acquisitions of Salix Pharmaceuticals Ltd and Dendreon Corp assets for smaller buys that fit into those businesses, Chief Executive Michael Pearson said on Monday.
Valeant announced on Sunday its largest-ever acquisition, the $10.1 billion cash purchase of Salix, ending a pause in major mergers and acquisitions for the deal-making company during its failed pursuit last year of Allergan Inc. The Salix deal is expected to close in the second quarter. (Reporting by Rod Nickel in Winnipeg, Manitoba)
© Thomson Reuters 2017 All rights reserved.